Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W, Zhenyu L, Shi M, Li H, Qiao J, Pan B, Zhao J, Wu Q, Zeng L, Niu M, Jing G, Zheng J, Xu K. Cao J, et al. Among authors: zeng l. Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29633386 Free article.
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, Yao M, Liu H, Li W, Zhang B, Sun K, Song X, Sun C, Jiao J, Qin Y, Sang T, Ma Y, Wu M, Gao X, Cheng H, Yan Z, Li D, Sun H, Zhu F, Wang Y, Zeng L, Li Z, Zheng J, Xu K. Sang W, et al. Among authors: zeng l. Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1. Cancer Med. 2020. PMID: 32608579 Free PMC article. Clinical Trial.
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
Shi M, Li L, Wang S, Cheng H, Chen W, Sang W, Qi K, Li Z, Wang G, Li H, Lan J, Huang J, Fei X, Yu M, Li F, Qiao J, Wu Q, Zeng L, Jing G, Zheng J, Gale RP, Xu K, Cao J. Shi M, et al. Among authors: zeng l. Am J Hematol. 2022 Jun 1;97(6):711-718. doi: 10.1002/ajh.26506. Epub 2022 Feb 25. Am J Hematol. 2022. PMID: 35179242 Free article.
Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
Wang X, Zhao L, Wang J, Yao Y, Wang J, Ji S, Hua T, Wang S, Cheng H, Shi M, Li Z, Zeng L, Zheng J, Xu K, Cao J. Wang X, et al. Among authors: zeng l. Front Immunol. 2022 Apr 27;13:814548. doi: 10.3389/fimmu.2022.814548. eCollection 2022. Front Immunol. 2022. PMID: 35572513 Free PMC article.
8,206 results